The Retinal Medicine Clinical Research Award is an annual initiative sponsored by EURETINA to support and encourage independent clinical research in the field of retinal medicine.
Clinician or non-clinician researchers, in a hospital or laboratory-based setting may conduct several types of clinical research, such as observational research studies, register studies (patient or disease registry), natural history / epidemiological studies, phase IV studies (post-authorisation safety studies, “PASS”), genomic research studies, pharmacovigilance studies, retrospective case-control studies, systematic reviews, meta-analyses and several other types of clinical studies.
The maximum budget that can be requested is €300,000 for up to two years. Appropriate justification is essential.
The competition is open to all clinicians and researchers, who’s current EURETINA membership commenced no later than March 2020, and who hold a full time clinical/research post at an EU-based clinical or academic research institute including H2020 associated countries* and the UK. Principal applicants and collaborators from industry are ineligible to apply. Please see further eligibility criteria below.
*(Iceland, Norway, Albania, Bosnia and Herzegovina, the former Yugoslav Republic of Macedonia, Montenegro, Serbia, Turkey, Israel, Moldova, Switzerland, Faroe Islands, Ukraine, Tunisia, Georgia, Armenia)
Funding may be available over 2 years (maximum duration) for the right project with suitable infrastructure and experience.
2020 EURETINA Clinical Research Award – Research Call Review Panel
Monday 1st February 2021 18.00 CET – Deadline for Expression of Interest
All eligible Expressions-of-Interest will be evaluated by the EURETINA Research Award Review Panel, from which short-listed entries will be invited to submit a full application.
Any queries prior to submission of an Expression-of-Interest application should be directed to email@example.com
Terms and Conditions
(a) I/we hold a full-time or affiliated post with an established EU-based (and H2020 associated countries and the UK) clinical or academic research institute, as named on my/our Expression-of-Interest submission.
(b) I/We have demonstrable prior experience in the conduct of clinical research in the field of retinal medicine and hold demonstrable GCP experience.
(c) I am/We are familiar and experienced with the administrative, insurance and regulatory requirements for the conduct of EU-based (and H2020 associated countries and the UK) clinical research studies.
(d) As Principal Applicant, I hold current EURETINA membership, that commenced no later than March 2020. EURETINA membership number is included on my Expression-of-Interest submission.
(e) I/We understand that my/our Expression-of-Interest will be evaluated by the EURETINA Retinal Medicine Clinical Research Award Review panel, who will generate a short-list of applicants to be invited to submit a full application to EURETINA. All decisions on Expressions-of-Interest and short-listed proposals made by EURETINA shall be final and no correspondence shall be entered into in relation to decisions made.
(f) I/We understand that members of the EURETINA Executive and Board Members are not eligible to apply.
(g) I/We understand that awardees from previous rounds of the EURETINA Retinal Medicine Clinical Research Award Programme are not eligible to apply.
(h) I/We understand that resubmission of an identical application from previous rounds of the EURETINA Retinal Medicine Clinical Research Award Programme is not permitted.
(i) As Principal Applicant, I understand that I am eligible to submit only one Expression-of- Interest.